AngioDynamics announces commercial launch of Auryon Atherectomy System in the United States

Over 170 New Jersey Auctions End Today - Bid Now
Over 1050 Total Lots Up For Auction at Three Locations - OK 05/12, CA 05/14, NJ 05/24

AngioDynamics announces commercial launch of Auryon Atherectomy System in the United States

Press releases may be edited for formatting or style | September 21, 2020 Cardiology
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the Auryon Atherectomy System, a newly-developed innovative technology for the treatment of Peripheral Artery Disease (PAD),including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR).

The Auryon Atherectomy System uses revolutionary technology to deliver powerful treatment of PAD lesions and occlusions. The Auryon Atherectomy System is the first laser atherectomy system to efficiently treat lesions of any type, length, or location (above and below the knee), with minimal impact on vessel walls1. The Auryon Atherectomy System uses solid-state laser technology for the treatment of PAD and is FDA cleared with an indication for treatment of infrainguinal stenoses and occlusions, including ISR.

“We strongly believe the Auryon Atherectomy System is a game-changer for the treatment of PAD, representing a true technological advancement in the treatment of these widespread and potentially fatal conditions,” said Jim Clemmer, AngioDynamics’ President and CEO. “We have already seen a very positive response from initial users of the Auryon System, which has led to a rapid expansion of markets and geographies. AngioDynamics is proud to make the Auryon Atherectomy System, and its solid-state laser technology, available to providers and patients nationwide.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified1,2. The System uses a 355nm wavelength laser platform, enabling the use of short UV laser pulses with targeted biological reactions that are effective in treating PAD while minimizing the risk of perforation and preserving the ability to vaporize lesions without thermal ablation3,4. During the Auryon Atherectomy System pivotal trial, 0% target lesion revascularization (TLR) was shown at 6 months2 after receiving treatment for ISR.

"Over the past 20 years, there has been a tremendous increase in endovascular techniques to treat peripheral artery disease (PAD), particularly in cases that might have otherwise required an amputation,” said Venkatesh Ramaiah, MD. “The Auryon Atherectomy System for infrainguinal lesions and in-stent restenosis has yielded excellent results without perforations, embolization, or other major complications. The solid-state, longer-wavelength and shorter-pulse approach differentiates the Auryon laser as a more efficient option across a wide range of plaque morphologies. This technology has the potential to save limbs and generally improve the quality of life for patients suffering from PAD.”

You Must Be Logged In To Post A Comment